The first BOADICEA prediction model integrated the risk due to the rare loss-of-function variants in the “major genes” (BRCA1 and 2, PALB2, CHEK2 and ATM) with tumor pathology (receptors status), basic demographic element (e.g., year and country of birth and family ethnicity), and family history [146]. This evidence concerns the gene CHEK2 and neoplasm.